Stay Informed on Key Developments

Investor News and Updates

Bill_Ipad

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 385 News
1 - 10of 385 News
September 10, 2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues 750 million euro hybrid bond
READ MORE
September 10, 2024
Not intended for UK Media – Late-breaking data from Phase III long-term study OASIS 3 presented at 2024 TMS Annual Meeting:
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
READ MORE
September 10, 2024
Not intended for U.S. and UK Media – Late-breaking data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ≥40% receiving finerenone had a reduced risk of new-onset diabetes
READ MORE
September 09, 2024
Not intended for U.S. and UK Media - Data from Phase I/II SOHO-01 trial presented at 2024 World Conference on Lung Cancer
New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
READ MORE
September 01, 2024
Not intended for U.S. and UK Media
Late-Breaking data from finerenone pooled analysis on cardiovascular and kidney outcomes and mortality in high-risk patient populations presented at ESC Congress 2024
READ MORE
September 01, 2024
Not intended for U.S. and UK - Media Late-Breaking data from pivotal Phase III FINEARTS-HF study presented at ESC Congress 2024
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure with high unmet medical need
READ MORE
August 29, 2024
Not intended for UK Media
Bayer starts Phase III trial in non-small cell lung cancer (NSCLC)
READ MORE
August 06, 2024
Second quarter of 2024
Bayer: Modest performance in challenging agricultural market environment – Group outlook confirmed
READ MORE
August 05, 2024
Not intended for U.S. and UK Media
Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction
READ MORE
August 01, 2024
Not intended for UK Media
Bayer submits New Drug Application to U.S. FDA for elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause
READ MORE
1 - 10of 385 News
1 - 10of 385 News
Inform Yourself on Special Topics
Control Weeds Not Farming

Control Weeds, Not Farming

LEARN MORE
Farmers discussing their weed management

Everything You Need to Know About Glyphosate

LEARN MORE
some-bayer-group-headquarters

Managing Glyphosate Litigation

learn more
woman harvesting carrots

Managing and Mitigating PCB Litigation Risk

learn more